You are now leaving Ogiviri.com, a Viatris Inc. company website.
The website you are about to access is not owned or controlled by Viatris. Links to the other websites are provided as a convenience to users and the inclusion of any link does not imply the endorsement of the linked site by Viatris. Viatris accepts no responsibility for the content of any linked sites.
Ogivri Prescribing Information. Mylan Inc. September 2019.
Rugo HS, Barve A, Waller CF, et al. Eﬀect of a proposed trastuzumab biosimilar compared with trastuzumab on overall response rate in patients with ERBB2 (HER2)–Positive metastatic breast cancer : a randomized clinical trial. JAMA. 2017;317:37-47.
Cardoso F, Bese N, Distelhorst SR, et al. Supportive care during treatment for breast cancer: resource allocations in low- and middle-income countries. A Breast Health Global Initiative 2013 consensus statement. The Breast. 2013;22:593-605.